| Document |
Document Title |
|
WO/2023/241233A1 |
The present invention provides a rupatifen fumarate crystal form C, and a preparation method therefor and the use thereof. By using Cu-Kα radiation, characteristic peaks of the X-ray powder diffraction pattern of the crystal form C of t...
|
|
WO/2023/236955A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a polysubstituted carbazole derivative and use thereof. The structural formula of the polysubstituted carbazole der...
|
|
WO/2023/238629A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1]. In general formula [1], Ar1 and Ar2 are each independently selected from among an aryl group and a heterocyclic group. Ar1 and...
|
|
WO/2023/239846A1 |
The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2023/231795A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a heterocyclic compound and the use thereof. The structural formula of the compound is as shown in formula (I). The...
|
|
WO/2023/234603A1 |
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device. The organic compound according to the present invention...
|
|
WO/2023/234671A1 |
The present invention relates to an organic compound used as a material for organic layers, such as an electron-transporting layer, in an organic light-emitting device. By employing the organic compound in organic layers, such as an elec...
|
|
WO/2023/231531A1 |
Provided are a nitrogen-containing compound, an organic electroluminescent apparatus and an electronic device. The nitrogen-containing compound has a structure as shown in formula I. When the nitrogen-containing compound is used in an or...
|
|
WO/2023/233285A1 |
The invention concerns a high refractive index monomer based on sulfur and/or selenium having general formula (I) and its use in the preparation of polymers, copolymers and photopolymers deriving therefrom through radical ring-opening me...
|
|
WO/2023/235880A1 |
The disclosure provides compounds of Formula (I) and salts thereof for use in medical treatment.
|
|
WO/2023/234749A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/234425A1 |
The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
|
|
WO/2023/225916A1 |
Disclosed is a method for preparing 4-thioflavone compound from a hydroxychalcone compound and xanthate, wherein the hydroxychalcone compound and the xanthate react in a solvent to prepare a thioflavone compound. In view of the huge appl...
|
|
WO/2023/230500A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds (I) that are inhibitors for spleen tyrosine kinase (Syk), which is a key signaling...
|
|
WO/2023/229430A1 |
The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
|
|
WO/2023/227697A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/229228A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device including same.
|
|
WO/2023/222115A1 |
Provided in the present application is a hydroxyamide derivative represented by formula (I), and a tautomer, stereoisomer, solvate, metabolite, isotopically-labeled compound, pharmaceutically acceptable salt or co-crystal thereof. The co...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/224413A1 |
The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of an organic light-emitting element.
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/218933A1 |
The present invention addresses the problem of providing a photoelectric conversion element which has excellent quantum efficiency when receiving blue light, an imaging element, a photosensor, and a compound. This photoelectric conversio...
|
|
WO/2023/217239A1 |
Disclosed are a pharmaceutical composition and use thereof. The present invention provides a pharmaceutical combination or a pharmaceutical composition. Active components of the pharmaceutical combination or the pharmaceutical compositio...
|
|
WO/2023/216669A1 |
The present application relates to an organic compound, an organic electroluminescent device, and an electronic device. The organic compound provided by the present application has a structure as shown in formula (1), and by applying the...
|
|
WO/2023/219071A1 |
Provided is a compound represented by formula (1).
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/220741A1 |
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulc...
|
|
WO/2023/217063A1 |
The present application provides a benzo[d]isoxazole compound and use thereof. The compound has a structure represented by the following formula I. The benzo[d]isoxazole compound of the present application can induce the degradation of B...
|
|
WO/2023/219456A1 |
The present invention relates to a quinoline derivative, a preparation method therefor, and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of cancer, autoimmune diseases, fibrosis, and...
|
|
WO/2023/213035A1 |
Disclosed is a method for preparing an aryl carbon glycoside compound including a gliflozin drug, belonging to the technical field of pharmaceutical chemistry. According to the present invention, a sulfinate glycosyl donor represented by...
|
|
WO/2023/213034A1 |
Disclosed are a sulfinate glycosyl donor, a method for preparing same, and use thereof, belonging to the technical field of pharmaceutical chemistry. The present invention particularly provides a sulfinate glycosyl donor represented by f...
|
|
WO/2023/215367A1 |
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2023/214815A1 |
The present invention relates to an organic compound used in an organic layer, such as an electron-blocking layer, a hole-transporting layer, etc., in an organic light-emitting device, and an organic light-emitting device having signific...
|
|
WO/2023/214788A1 |
The present invention relates to an organic compound used in organic layers, such as electron-blocking layers and hole transport layers, within an organic light-emitting diode, and an organic light-emitting diode that adopts the organic ...
|
|
WO/2023/207241A1 |
The present invention relates to a halogen-substituted isoindoline compound represented by formula I below and use thereof. The compound of the present invention has significantly better anti-tumor activity, and can be prepared into an o...
|
|
WO/2023/205892A1 |
The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group (1a), 1b) and (1c), that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is...
|
|
WO/2023/210772A1 |
A first problem to be addressed by the present invention is to provide a photoelectric conversion element that has excellent quantum efficiency when receiving blue light. A second problem to be addressed by the present invention is to pr...
|
|
WO/2023/207881A1 |
Provided herein are novel compounds, for example, compounds having a Formula A, B, C, D, E, or F, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
|
|
WO/2023/211940A1 |
The present disclosure provides STING agonists, and compositions, formulations. and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/209692A1 |
The present disclosure relates to inhibitors of Rho-associated protein kinase (ROCK), pharmaceutical compositions comprising the same, and use thereof for the prevention or treatment of a disease mediated by the ROCK. Particularly, the i...
|
|
WO/2023/208108A1 |
Disclosed herein is a compound for reducing uric acid, which is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. The present invention can significantly reduce the serum uric acid level in a ra...
|
|
WO/2023/211063A1 |
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting element. The organic compound according to the present inventio...
|
|
WO/2023/207375A1 |
The present application relates to a nitrogen-containing compound, an electronic element, and an electronic device. The nitrogen-containing compound has a structure represented by formula I, and can improve the performance of electronic ...
|
|
WO/2023/211213A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport and injection ability, light-emitting abilit...
|
|
WO/2023/210520A1 |
Provided are: a resist composition having favorable sensitivity, roughness characteristics, and etching resistance; a resist pattern formation method; and a new compound that is useful as a resin component for said resist composition. Th...
|
|
WO/2023/201423A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2023/201421A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2023/205173A1 |
Described herein are compounds that are glutaminyl-peptide cyclotransferase like (QPCTL) protein modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using su...
|
